SARS-CoV-2 infection in adults and HIV: an update

Aim COVID-19 pandemic caused by SARS-CoV-2 is spreading throughout the world affecting both healthy individuals and people with underlying immune-deficiencies. People living with human immunodeficiency virus (HIV) consist a group multiply affected by this universal crisis. Methods Literature search aiming to identify relevant publications referring to the consequences of the COVID-19 pandemic in HIV infected population. Results A body of literature is rapidly growing in regard to epidemiological data, the interaction between HIV and SARS-CoV-2, and clinical outcome in people living with HIV. Intensive research is warranted to identify any interactions of the co-existence of the two viruses in the immune system of HIV infected patients as common pathophysiology and molecular aspects are recognized. Human relations are diminished as a result of the social measures, and detailed recording of the consequences in this population is needed. Conclusion Further research could shed light on the common underlying molecular mechanisms of both conditions in an attempt to discover treatment regimens for SARS-CoV-2 infection

Mid-term outcomes in the treatment of retroperitoneal sarcomas: a 12-year single-institution experience

Aim To present the experience from collective data regarding patients with retroperitoneal sarcomas that have been operated in and followed up by the University General Hospital of Patras in Rion, Greece, between 2009 and 2020. Methods A retrospective analysis of adult patients treated at our hospital with a diagnosis of primary retroperitoneal sarcoma who underwent tumour resection. Results Data from 29 patients were analysed. The mean age at diagnosis was 56.1 years; 55.2% of patients were male (n=16). Liposarcomas (on histology) were identified in 19 (65.5%) patients, leiomyosarcoma six (20.7%), and other histologic subtypes in four (13.8%) patients. Tumours >5cm were presented in 27 (93.1%) patients. Negative margins were attained in 13 (44.8%) of all patients who underwent surgical resection. Five (17.2%) patients received neoadjuvant radiation, four (13.8%) postoperative radiation, and three (10.3%) patients received both chemotherapy and radiation prior to surgery with the rest of the patients being treated with surgical excision alone. A 3-year follow-up was successful in 21 (72.4%) patients; five (23.8%) patients died. In total, 16 (55.2%) patients were found to have a local recurrence, with no significant difference in patients' age, gender, tumour size, histology, negative surgical margin (Ro) resection, neoadjuvant chemotherapy, or radiation therapy. There was a significant difference in the 3-year survival rate between patients having positive or negative surgical margins (p=0.027). Conclusion The higher 3-year survival rate in patients with retroperitoneal sarcomas when achieving Ro resection warrant further investigation with a larger sample size across different institutions